Mednet Logo
HomeMedical OncologyQuestion

Would you consider atezolizumab-bevacizumab combination in a patient with metastatic hepatocellular carcinoma who presented with paraneoplastic myasthenia gravis?

1 Answers
Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic, Rochester

Paraneoplastic myasthenia gravis from HCC is extremely rare with only a few handful of cases have ever been reported (Choi et al. AJG 2018; Fussner et al. Neurology 2019; Vautravers et al., PMID 19046712). The mechanism of pathogenesis is not known although it is thought to be related to the cross r...

Register or Sign In to see full answer